-transparent.png){kind=logo}
We have established the content and molecular species of immunoreactive beta-endorphin (ir-beta-END) and immunoreactive N-acetyl-endorphin (ir-Nac-END) in rat neurointermediate lobe by specific radioimmunoassay (RIA) and high-performance liquid chromatography after chronic administration of dopamine (DA) agonists and antagonists. The DA agonist, bromocriptine, reduces tissue levels of all major immunoreactive species, in particular the C-terminally shortened N-acetylated forms. The DA antagonist, haloperidol, proportionally increases all immunoreactive forms, except Nac-beta-END, thus altering the relative abundance of this species. These data indicate that DA is involved in the control of both tissue levels and processing of beta-END-like peptides in the rat neurointermediate lobe.
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
October 1987,
The Journal of pharmacology and experimental therapeutics,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
August 1984,
Endocrinology,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
April 1984,
Life sciences,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
June 1984,
Endocrinology,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
May 1989,
Neuroendocrinology,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
December 1984,
Biochemical Society transactions,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
January 1984,
Clinical and experimental pharmacology & physiology,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
November 1989,
Molecular and cellular endocrinology,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
January 1986,
Endocrinology,
D J Autelitano, and
A I Smith, and
S J Lolait, and
J W Funder
June 1981,
The Journal of neuroscience : the official journal of the Society for Neuroscience,
